Transcript Opportunities for Trainees to Promote Diversity

OPPORTUNITIES FOR TRAINEES TO
PROMOTE DIVERSITY
March 23, 2010
NSF Minority Faculty Development Workshop
Alexis Bakos, PhD, MPH, RN,C
Chief, Diversity Training Branch
Center to Reduce Cancer Health Disparities,
NCI
Continuing Umbrella of Research Experiences
HS
Undergrad
Predoctoral
Postdoctoral
Junior Investigator
NRSA Fellowships: F31 and T32 S
Diversity
Supplements
Supplements to
the CURE:
Cancer
Center
Grant: P30
Career
Development
R
03
SPORE: P50 Translational
Cancer Center: P30 MD/POR
R25T:
Prevention and
Control
Clinical Oncology
Training Grants: K12
Career Awards
K01 K08 K23
Transition
Career: K22
R
21
R
0
1
Supplement Eligibility
Eligible Individuals
 Ethnic and/or racial minorities
 Socio-economically disadvantaged groups
 First generation college graduates
 Individuals with disabilities
 Must be US Citizen or permanent resident
Eligible Grants
■ NCI grants
Receipt of Supplement
Applications by the NCI
■ Application Receipt: Two Cycles
■ October 1 through December 1
■ March 1 through May 1
■ Notice of Award: Office of Grants Administration
Research Supplements to Promote
Diversity in Health Related Research
■ Available for every career level e.g. High
School through Junior faculty
■ Provides up to five years of support
■ * For T32, R25T, and K12 the supplement is
awarded after slots are filled
http://grants.nih.gov/grants/guide/pa-files/PA-08-190-html
Supplements to Promote Reentry
into Biomedical and Behavioral
Research Careers





Available for individuals who want to reestablish active
research careers
Provides up to 3 years of support
Period of career interruption is 1 to 8 years
Candidate must have a doctoral degree
Support for salary, fringe benefits, supplies and travel
http://grants.nih.gov/grants/guide/pa-files/PA-08-191.html
Exploratory Grant Award to Promote Workforce
Diversity in Basic Cancer Research




Mechanism: R21 (PAR-09-162)
Purpose: To increase the diversity of the research
workforce by supporting investigators from
diverse populations in the area of basic cancer
research.
Direct Cost: $275,000 for 2 years
Receipt Dates: Nov 23rd and June 23rd
Exploratory/Developmental Grants Program for
Basic Cancer Research in Cancer Health Disparities




Mechanism: R21 (PAR-09-160)
Purpose: To promote basic cancer research
expertise in cancer health disparities
Direct Cost: $275,000 for 2 yrs
Receipt Date: Nov 23rd and June 23rd
Basic Cancer Research in Cancer Health Disparities


Mechanism: U01 (PAR-09-161)
Cooperative agreement FOA to conduct basic
research into the causes and treatment of cancer
health disparities





New methodologies
Secondary data analyses
Innovative mechanistic studies
$250,000/yr for up to 5 yrs
Receipt Date: Nov 23rd and June 23rd
Office of Technology & Industrial Relations (OTIR)
Innovative Technology Development for Cancer
Research




Mechanism R21 (RFA-CA-10-005)
Feasibility studies on early stage development
(i.e., at their conceptual stage where feasibility
has not been established) of cancer-relevant
technologies in the area of CA biology,
prevention, diagnosis, treatment, epidemiology &
cancer health disparities
Up to $500,000 over 3 yr period
Receipt Date: May 27 and Sept. 30, 2010
Office of Technology & Industrial Relations (OTIR)
Application & Early Stage Development of Emerging
Technology in Cancer Research




Mechanism: R21 (RFA-CA-10-003)
Feasibility studies on emerging cancer-relevant
technologies (i.e., has passed the initial development
stage but hasn’t been evaluated within the context of
its intended use) in the area of CA biology,
prevention, diagnosis, treatment, epidemiology &
cancer health disparities
Up to $275,000 direct costs over 2 yrs
Receipt Date: May 27 and Sept. 30, 2010
Office of Technology & Industrial Relations (OTIR)
Innovative & Early-Stage Development of Emerging
Technologies in Biospecimen Science




Mechanism R21 (RFA-CA-10-001)
Early stage studies that develop technologies
capable of interrogating &/or maximizing the
quality & utility of biospecimens
Up to $275,000 direct costs over 2 yrs
Receipt Date: May 27 and Sept. 30, 2010
■ Creates a pipeline of diverse cancer
investigators
■ Investigators become mentors
Example:
Manuel Penichet, UCLA
Recipient of:
*Diversity Supplement
*K award
*R01s
Manuel Penichet, M.D., Ph.D.
Dr. Penichet and trainees
DTB Contacts
•
For Supplements
• Peter Ogunbiyi: [email protected]

For R21 & U01 Funding Opportunities
 Anil Wali: [email protected]

For OTIR Funding Opportunities
 LeeAnn Bailey: [email protected]